Archives
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Conflict of interest br Funding br Acknowledgements br
2022-08-15
Conflict of interest Funding Acknowledgements Introduction to SLC6 transporters The solute carrier (SLC) 6 family of membrane proteins perform the Na+-coupled symport of amino acids and amino GNF 2 mg derivatives into cells throughout the body. Disrupting neurotransmitter SLC6-mediated
-
br Financial support This work was supported by Fondation po
2022-08-13
Financial support This work was supported by Fondation pour la Recherche Médicale (Equipe labellisée, DEQ20150331724), Inserm, University of Lille, and Agence Nationale pour la Recherche (ANR-10-LBEX-46 and ANR-10-INBS-08; ProFI project, “Infrastructures Nationales en Biologie et Santé”; “Investi
-
br Materials and methods br Author contributions br Acknowle
2022-08-12
Materials and methods Author contributions Acknowledgments We thank members of the Skaar laboratory for critical evaluation of the manuscript. This work was supported by grants from the National Institutes of Health, R01AI069233 (EPS), and T32GM008554-21 (LJL). Introduction Pseudomonas
-
Introduction Multiple sclerosis MS a neurological autoimmune
2022-08-12
Introduction Multiple sclerosis (MS), a neurological autoimmune disease, is driven by CD4+ 2-Palmitoylglycerol of the T helper (TH) cells [1]. There is no curative treatment for MS and the present treatments typically focus on immunomodulation for slowing the progression of the disease. These incl
-
Our synthetic approach to GPR antagonists was designed
2022-08-12
Our synthetic approach to GPR55 antagonists was designed so that many different structures could be accessed to rapidly explore initial SAR, along with validating or modifying our current model (). The synthesis begins with the coupling of a carboxylic ML-193 synthesis to 4-piperidone by first form
-
Several studies have found that GPR possesses
2022-08-12
Several studies have found that GPR55 possesses a distinct pharmacology from that of CB1 and CB2, and that only certain cannabinoids act at this receptor. In transfected neostigmine bromide expressing hGPR55, out of more than 20 synthetic and endogenous cannabinoids evaluated, only 2 compounds, SR1
-
br Introduction High dose niacin or nicotinic acid has
2022-08-12
Introduction High dose niacin, or nicotinic acid, has been used as an athero-protective drug for more than 50 years (Carlson, 2005, Offermanns, 2006). When taken in pharmacological doses (>1g/day), the nicotinic survivin (baculoviral IAP repeat-containing protein 5) (21-28) australia form of nia
-
Treatment with probiotics can also be used to alter the
2022-08-12
Treatment with probiotics can also be used to alter the microbiota profile of CF patients. One study reports that administration of the probiotic Lactobacillus Reuteri improved digestive health and inflammation [112]. The fecal microbial profile changed, showing a decrease in Proteobacteria and an i
-
br Evolution of multiple GnRH forms and GnRH receptors acros
2022-08-12
Evolution of multiple GnRH forms and GnRH receptors across vertebrates GnRH is an evolutionary ancient peptide that first appears prior to the protostome-deuterostome split, and is a member of the GnRH-adipokinetic hormone-corazonin superfamily of peptides (Roch et al., 2011, Roch et al., 2014).
-
In conclusi http www apexbt com media diy images
2022-08-12
In conclusion, Glu transactions in glia cells are mediated through Glu receptors and transporters. From a biochemical perspective, the specificity of the cascades has started to be elucidated. A model of our present findings is depicted in Fig. 6. Acknowledgements This work was supported by Gran
-
br Experimental Procedures br Acknowledgments This work was
2022-08-12
Experimental Procedures Acknowledgments This work was supported by NIH/National Human Genome Research Institute (NHGRI) R00 HG006922 and NIH/NHGRI R01 HG008974 (to J.G.), the Huntsman Cancer Institute, and the Women’s Cancers Disease-Oriented Team at the Huntsman Cancer Institute. Research rep
-
cc-5013 Previous researches about ghrelin focused primarily
2022-08-12
Previous researches about ghrelin focused primarily on gastrointestinal functions [30], energy balance [31], weight [32], and more recently on anxiety [33], [34], [35] and depression [36]. Here, we provided the first demonstration that chronic peripheral or central ghrelin treatment to CUMS rodents
-
br Regulation of plasma ghrelin concentration
2022-08-12
Regulation of plasma ghrelin concentration As described above, ghrelin is primarily produced in the stomach and secreted into the blood stream. Plasma ghrelin does not significantly differ between chronic heart failure (CHF) patients and controls, although plasma ghrelin level is significantly hi
-
We hypothesize that HBO increases GABA activity at
2022-08-12
We hypothesize that HBO2 increases GABA activity at the GABAA receptor via a nitric oxide dependent mechanism. Blotting for the phosphorylated β3 subunit of the GABAA receptor should theoretically be increased when there is more GABA activity at the receptor (McDonald et al., 1998). We expected that
-
Till date the first line treatment of T DM
2022-08-11
Till date, the first line treatment of T2DM is oral metformin followed by oral sulfonylureas, dipeptidyl peptidase-IV-inhibitors, and TZDs. As the disease progresses, injectable glucagon-like peptide-I analogues or ultimately insulin become necessary to maintain glycaemic control. Despite the establ
11089 records 81/740 page Previous Next First page 上5页 8182838485 下5页 Last page